HPLC Method for Analysis of Nirmatrelvir in PAXLOVID™ (Nirmatrelvir Tablets) on Primesep P Column

HPLC Method for Nirmatrelvir on Primesep P by SIELC Technologies

High Performance Liquid Chromatography (HPLC) Method for Analysis of Nirmatrelvir.

Nirmatrelvir is an antiviral medication with the chemical formula C23H32F3N5O4. It is a part of a medical combination used to treat COVID-19. It works through inhibiting 3C-like protease. From November 2021, Nirmatrelvir has been allowed to be manufactured and sold in over 95 countries to ensure greater access to the global population.

Nirmatrelvir can be retained and analyzed using the Primesep P stationary phase column. The analysis utilizes a gradient method with a simple mobile phase consisting of water and acetonitrile (MeCN). Detection is performed using UV.

Condition
Column Primesep P, 3.2 x 100 mm, 5 µm, 100 A, dual ended
Mobile Phase Gradient MeCN – 10-90%
Buffer No
Flow Rate 0.5 ml/min
Detection UV 210nm

Description
Class of Compounds Drug
Analyzing Compounds Nirmatrelvir

 

Application Column

Primesep P

Column Diameter: 3.2 mm
Column Length: 100 mm
Particle Size: 5 µm
Pore Size: 100 A
Column options: dual ended

Add to cart
Application Analytes:
Nirmatrelvir
Application Detection:
UV Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.